CliffBio
small molecule

CAMCEVI KIT

LEUPROLIDE MESYLATE

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry
CompanyAccord Biopharma →View the full company profile on CliffBio

Drug detail

Brand nameCAMCEVI KIT
Active ingredientLEUPROLIDE MESYLATE
StrengthEQ 42MG BASE
Dosage formEMULSION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalMay 2021
Marketing statusRX

Listed patents

PatentExpiresType
11717555January 2039product
12133878December 2037product
9572857August 2029product
10646572January 2027product
9744207January 2027product

More from Accord Biopharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CAMCEVI KIT patent cliff — loss of exclusivity January 2039 | CliffBio